The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
After ZW171's exit, ZW251 enters the clinic.
Petosemtamab's phase 2 data in this setting should come by the year end.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
